ID   PEAK1_HUMAN             Reviewed;        1746 AA.
AC   Q9H792; Q6ZS78; Q8NAZ4; Q8NCM3; Q8TEG7;
DT   03-OCT-2006, integrated into UniProtKB/Swiss-Prot.
DT   10-FEB-2009, sequence version 4.
DT   12-OCT-2022, entry version 168.
DE   RecName: Full=Inactive tyrosine-protein kinase PEAK1 {ECO:0000305};
DE   AltName: Full=Pseudopodium-enriched atypical kinase 1 {ECO:0000303|PubMed:20534451};
DE   AltName: Full=Sugen kinase 269 {ECO:0000303|PubMed:29212708};
DE   AltName: Full=Tyrosine-protein kinase SgK269;
GN   Name=PEAK1; Synonyms=KIAA2002;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16572171; DOI=10.1038/nature04601;
RA   Zody M.C., Garber M., Sharpe T., Young S.K., Rowen L., O'Neill K.,
RA   Whittaker C.A., Kamal M., Chang J.L., Cuomo C.A., Dewar K.,
RA   FitzGerald M.G., Kodira C.D., Madan A., Qin S., Yang X., Abbasi N.,
RA   Abouelleil A., Arachchi H.M., Baradarani L., Birditt B., Bloom S.,
RA   Bloom T., Borowsky M.L., Burke J., Butler J., Cook A., DeArellano K.,
RA   DeCaprio D., Dorris L. III, Dors M., Eichler E.E., Engels R., Fahey J.,
RA   Fleetwood P., Friedman C., Gearin G., Hall J.L., Hensley G., Johnson E.,
RA   Jones C., Kamat A., Kaur A., Locke D.P., Madan A., Munson G., Jaffe D.B.,
RA   Lui A., Macdonald P., Mauceli E., Naylor J.W., Nesbitt R., Nicol R.,
RA   O'Leary S.B., Ratcliffe A., Rounsley S., She X., Sneddon K.M.B.,
RA   Stewart S., Sougnez C., Stone S.M., Topham K., Vincent D., Wang S.,
RA   Zimmer A.R., Birren B.W., Hood L., Lander E.S., Nusbaum C.;
RT   "Analysis of the DNA sequence and duplication history of human chromosome
RT   15.";
RL   Nature 440:671-675(2006).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 537-1746.
RC   TISSUE=Lung, Mesangial cell, and Smooth muscle;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 707-1120.
RC   TISSUE=Spleen;
RA   Jikuya H., Takano J., Nomura N., Kikuno R., Nagase T., Ohara O.;
RT   "The nucleotide sequence of a long cDNA clone isolated from human spleen.";
RL   Submitted (JAN-2002) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 983-1746.
RC   TISSUE=Brain;
RX   PubMed=12056414; DOI=10.1093/dnares/9.2.47;
RA   Ohara O., Nagase T., Mitsui G., Kohga H., Kikuno R., Hiraoka S.,
RA   Takahashi Y., Kitajima S., Saga Y., Koseki H.;
RT   "Characterization of size-fractionated cDNA libraries generated by the in
RT   vitro recombination-assisted method.";
RL   DNA Res. 9:47-57(2002).
RN   [5]
RP   IDENTIFICATION.
RX   PubMed=12471243; DOI=10.1126/science.1075762;
RA   Manning G., Whyte D.B., Martinez R., Hunter T., Sudarsanam S.;
RT   "The protein kinase complement of the human genome.";
RL   Science 298:1912-1934(2002).
RN   [6]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-540 AND SER-587, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [8]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [9]
RP   FUNCTION, INTERACTION WITH BCAR1 AND CRK, SUBCELLULAR LOCATION, AND
RP   PHOSPHORYLATION BY CSK.
RX   PubMed=20534451; DOI=10.1073/pnas.0914776107;
RA   Wang Y., Kelber J.A., Tran Cao H.S., Cantin G.T., Lin R., Wang W.,
RA   Kaushal S., Bristow J.M., Edgington T.S., Hoffman R.M., Bouvet M.,
RA   Yates J.R. III, Klemke R.L.;
RT   "Pseudopodium-enriched atypical kinase 1 regulates the cytoskeleton and
RT   cancer progression.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:10920-10925(2010).
RN   [10]
RP   ERRATUM OF PUBMED:20534451.
RA   Wang Y., Kelber J.A., Tran Cao H.S., Cantin G.T., Lin R., Wang W.,
RA   Kaushal S., Bristow J.M., Edgington T.S., Hoffman R.M., Bouvet M.,
RA   Yates J.R. III, Klemke R.L.;
RL   Proc. Natl. Acad. Sci. U.S.A. 107:13556-13556(2010).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-281 AND TYR-635, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [12]
RP   PHOSPHORYLATION AT TYR-665, MUTAGENESIS OF TYR-665, SUBCELLULAR LOCATION,
RP   AND FUNCTION.
RX   PubMed=23105102; DOI=10.1074/jbc.m112.410910;
RA   Bristow J.M., Reno T.A., Jo M., Gonias S.L., Klemke R.L.;
RT   "Dynamic phosphorylation of tyrosine 665 in pseudopodium-enriched atypical
RT   kinase 1 (PEAK1) is essential for the regulation of cell migration and
RT   focal adhesion turnover.";
RL   J. Biol. Chem. 288:123-131(2013).
RN   [13]
RP   FUNCTION, INTERACTION WITH SHC1, PHOSPHORYLATION AT TYR-1188, MUTAGENESIS
RP   OF TYR-1188, IN COMPLEX WITH PPP1CA, PPP1CC AND SHC1, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY.
RX   PubMed=23846654; DOI=10.1038/nature12308;
RA   Zheng Y., Zhang C., Croucher D.R., Soliman M.A., St-Denis N.,
RA   Pasculescu A., Taylor L., Tate S.A., Hardy W.R., Colwill K., Dai A.Y.,
RA   Bagshaw R., Dennis J.W., Gingras A.C., Daly R.J., Pawson T.;
RT   "Temporal regulation of EGF signalling networks by the scaffold protein
RT   Shc1.";
RL   Nature 499:166-171(2013).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-281; SER-572; SER-587;
RP   SER-648; SER-854; SER-898; THR-1151 AND SER-1374, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [15]
RP   LACK OF ATP-BINDING.
RX   PubMed=24107129; DOI=10.1042/bj20131174;
RA   Murphy J.M., Zhang Q., Young S.N., Reese M.L., Bailey F.P., Eyers P.A.,
RA   Ungureanu D., Hammaren H., Silvennoinen O., Varghese L.N., Chen K.,
RA   Tripaydonis A., Jura N., Fukuda K., Qin J., Nimchuk Z., Mudgett M.B.,
RA   Elowe S., Gee C.L., Liu L., Daly R.J., Manning G., Babon J.J., Lucet I.S.;
RT   "A robust methodology to subclassify pseudokinases based on their
RT   nucleotide-binding properties.";
RL   Biochem. J. 457:323-334(2014).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-1151, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [17]
RP   SUBUNIT, INTERACTION WITH PRAG1, AND MUTAGENESIS OF PHE-1609.
RX   PubMed=29079850; DOI=10.1038/s41467-017-01279-9;
RA   Patel O., Griffin M.D.W., Panjikar S., Dai W., Ma X., Chan H., Zheng C.,
RA   Kropp A., Murphy J.M., Daly R.J., Lucet I.S.;
RT   "Structure of SgK223 pseudokinase reveals novel mechanisms of homotypic and
RT   heterotypic association.";
RL   Nat. Commun. 8:1157-1157(2017).
RN   [18]
RP   VARIANTS [LARGE SCALE ANALYSIS] ARG-213; ILE-240; PRO-440; GLN-611;
RP   ILE-792; GLU-836; PHE-1035; LYS-1071; PRO-1077; LEU-1145; GLN-1408;
RP   THR-1542 AND GLY-1699.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [19] {ECO:0007744|PDB:6BHC}
RP   X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 1272-1743, MUTAGENESIS OF
RP   ALA-1707, SUBUNIT, AND DOMAIN.
RX   PubMed=29212708; DOI=10.1074/jbc.ra117.000751;
RA   Ha B.H., Boggon T.J.;
RT   "The crystal structure of pseudokinase PEAK1 (Sugen kinase 269) reveals an
RT   unusual catalytic cleft and a novel mode of kinase fold dimerization.";
RL   J. Biol. Chem. 293:1642-1650(2018).
CC   -!- FUNCTION: Probable catalytically inactive kinase. Scaffolding protein
CC       that regulates the cytoskeleton to control cell spreading and migration
CC       by modulating focal adhesion dynamics (PubMed:23105102,
CC       PubMed:20534451). Acts as a scaffold for mediating EGFR signaling
CC       (PubMed:23846654). {ECO:0000269|PubMed:20534451,
CC       ECO:0000269|PubMed:23105102, ECO:0000269|PubMed:23846654}.
CC   -!- SUBUNIT: Homodimer (PubMed:29212708). Interacts with BCAR1 and CRK
CC       (PubMed:20534451). Interacts with PRAG1 (PubMed:29079850). Interacts
CC       (when phosphorylated at Tyr-1188) with SHC1 (via PID domain)
CC       (PubMed:23846654). Found in a complex with PPP1CA, PPP1CC, SHC1 and
CC       PEAK1. {ECO:0000269|PubMed:20534451, ECO:0000269|PubMed:23846654,
CC       ECO:0000269|PubMed:29079850, ECO:0000269|PubMed:29212708}.
CC   -!- INTERACTION:
CC       Q9H792; P56945: BCAR1; NbExp=3; IntAct=EBI-2609701, EBI-702093;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton
CC       {ECO:0000269|PubMed:20534451, ECO:0000269|PubMed:23105102}. Cell
CC       junction, focal adhesion {ECO:0000269|PubMed:20534451,
CC       ECO:0000269|PubMed:23105102}. Note=Colocalizes with F-actin in serum-
CC       rich medium (PubMed:20534451). Actin colocalization is reduced during
CC       serum starvation (PubMed:20534451). {ECO:0000269|PubMed:20534451}.
CC   -!- DOMAIN: The dimerization region encompasses helices both from the
CC       N- and C-terminal of the protein kinase domain.
CC       {ECO:0000269|PubMed:29212708}.
CC   -!- PTM: Phosphorylated on tyrosine in a CSK-dependent manner in response
CC       to adhesion to fibronectin and to EGF stimulation (PubMed:20534451).
CC       Phosphorylation at Tyr-665 by a Src family kinase controls subcellular
CC       localization to focal adhesion and focal adhesion dynamics
CC       (PubMed:20534451). Phosphorylation at Tyr-1188 is essential for binding
CC       to SHC1 (PubMed:23846654). {ECO:0000269|PubMed:20534451,
CC       ECO:0000269|PubMed:23846654}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. {ECO:0000305}.
CC   -!- CAUTION: Has been the subject of controversy surrounding its catalytic
CC       capabilities. Early characterization of PEAK1 gave a weak in vitro
CC       tyrosine kinase activity (PubMed:20534451). The crystal structure
CC       indicates that the kinase-domain contains a closed nucleotide-binding
CC       cleft that in this conformation may deleteriously affect nucleotide
CC       binding (PubMed:29212708). Furthermore PEAK1 is devoid of nucleotide
CC       binding activity, as detected by a thermal-shift assay
CC       (PubMed:24107129). So it seems probable that PEAK1 is an inactive
CC       kinase. {ECO:0000269|PubMed:20534451, ECO:0000269|PubMed:24107129,
CC       ECO:0000269|PubMed:29212708}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAB15006.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC       Sequence=BAC87076.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AC087465; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC107883; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AK024793; BAB15006.1; ALT_INIT; mRNA.
DR   EMBL; AK091802; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; AK127658; BAC87076.1; ALT_INIT; mRNA.
DR   EMBL; AK074157; BAB84983.1; -; mRNA.
DR   EMBL; AB082533; BAC02711.1; -; mRNA.
DR   CCDS; CCDS42062.1; -.
DR   RefSeq; NP_079052.2; NM_024776.3.
DR   RefSeq; XP_005254727.1; XM_005254670.2.
DR   RefSeq; XP_005254728.1; XM_005254671.2.
DR   RefSeq; XP_005254730.1; XM_005254673.2.
DR   RefSeq; XP_005254731.1; XM_005254674.2.
DR   RefSeq; XP_005254732.1; XM_005254675.4.
DR   RefSeq; XP_011520335.1; XM_011522033.2.
DR   RefSeq; XP_011520336.1; XM_011522034.2.
DR   RefSeq; XP_011520337.1; XM_011522035.2.
DR   RefSeq; XP_011520338.1; XM_011522036.2.
DR   RefSeq; XP_011520339.1; XM_011522037.2.
DR   RefSeq; XP_011520340.1; XM_011522038.2.
DR   RefSeq; XP_011520341.1; XM_011522039.2.
DR   PDB; 6BHC; X-ray; 2.30 A; A=1272-1743.
DR   PDBsum; 6BHC; -.
DR   AlphaFoldDB; Q9H792; -.
DR   SMR; Q9H792; -.
DR   BioGRID; 122926; 123.
DR   DIP; DIP-56276N; -.
DR   IntAct; Q9H792; 78.
DR   MINT; Q9H792; -.
DR   STRING; 9606.ENSP00000452796; -.
DR   BindingDB; Q9H792; -.
DR   ChEMBL; CHEMBL3627585; -.
DR   GlyConnect; 1692; 11 N-Linked glycans (1 site).
DR   GlyGen; Q9H792; 2 sites, 11 N-linked glycans (1 site), 1 O-linked glycan (1 site).
DR   iPTMnet; Q9H792; -.
DR   PhosphoSitePlus; Q9H792; -.
DR   BioMuta; PEAK1; -.
DR   DMDM; 223634730; -.
DR   EPD; Q9H792; -.
DR   jPOST; Q9H792; -.
DR   MassIVE; Q9H792; -.
DR   MaxQB; Q9H792; -.
DR   PaxDb; Q9H792; -.
DR   PeptideAtlas; Q9H792; -.
DR   PRIDE; Q9H792; -.
DR   ProteomicsDB; 81090; -.
DR   Antibodypedia; 7598; 217 antibodies from 28 providers.
DR   DNASU; 79834; -.
DR   Ensembl; ENST00000312493.5; ENSP00000309230.4; ENSG00000173517.11.
DR   Ensembl; ENST00000560626.6; ENSP00000452796.2; ENSG00000173517.11.
DR   Ensembl; ENST00000682557.1; ENSP00000507603.1; ENSG00000173517.11.
DR   GeneID; 79834; -.
DR   KEGG; hsa:79834; -.
DR   MANE-Select; ENST00000682557.1; ENSP00000507603.1; NM_001385026.1; NP_001371955.1.
DR   UCSC; uc059lyw.1; human.
DR   CTD; 79834; -.
DR   DisGeNET; 79834; -.
DR   GeneCards; PEAK1; -.
DR   HGNC; HGNC:29431; PEAK1.
DR   HPA; ENSG00000173517; Low tissue specificity.
DR   MIM; 614248; gene.
DR   neXtProt; NX_Q9H792; -.
DR   OpenTargets; ENSG00000173517; -.
DR   VEuPathDB; HostDB:ENSG00000173517; -.
DR   eggNOG; ENOG502QVUZ; Eukaryota.
DR   GeneTree; ENSGT00940000157591; -.
DR   HOGENOM; CLU_002882_0_0_1; -.
DR   InParanoid; Q9H792; -.
DR   OMA; MGWNRNR; -.
DR   OrthoDB; 49921at2759; -.
DR   PhylomeDB; Q9H792; -.
DR   PathwayCommons; Q9H792; -.
DR   Reactome; R-HSA-9013420; RHOU GTPase cycle.
DR   Reactome; R-HSA-9013424; RHOV GTPase cycle.
DR   SignaLink; Q9H792; -.
DR   BioGRID-ORCS; 79834; 9 hits in 1051 CRISPR screens.
DR   ChiTaRS; PEAK1; human.
DR   GenomeRNAi; 79834; -.
DR   Pharos; Q9H792; Tchem.
DR   PRO; PR:Q9H792; -.
DR   Proteomes; UP000005640; Chromosome 15.
DR   RNAct; Q9H792; protein.
DR   Bgee; ENSG00000173517; Expressed in skin of hip and 187 other tissues.
DR   ExpressionAtlas; Q9H792; baseline and differential.
DR   Genevisible; Q9H792; HS.
DR   GO; GO:0015629; C:actin cytoskeleton; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-KW.
DR   GO; GO:0005925; C:focal adhesion; IDA:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IDA:UniProtKB.
DR   GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0004672; F:protein kinase activity; IBA:GO_Central.
DR   GO; GO:0016477; P:cell migration; IDA:UniProtKB.
DR   GO; GO:0048041; P:focal adhesion assembly; IMP:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IBA:GO_Central.
DR   GO; GO:0051893; P:regulation of focal adhesion assembly; IDA:UniProtKB.
DR   GO; GO:0034446; P:substrate adhesion-dependent cell spreading; IDA:UniProtKB.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell junction; Cytoplasm; Cytoskeleton; Phosphoprotein;
KW   Reference proteome.
FT   CHAIN           1..1746
FT                   /note="Inactive tyrosine-protein kinase PEAK1"
FT                   /id="PRO_0000250589"
FT   DOMAIN          1313..1675
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          44..66
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          334..411
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          489..517
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          551..577
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          671..700
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          713..764
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          802..920
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1052..1102
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1138..1158
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1285..1311
FT                   /note="Required for homodimerization"
FT                   /evidence="ECO:0000269|PubMed:29212708"
FT   REGION          1402..1456
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1670..1743
FT                   /note="Required for homodimerization"
FT                   /evidence="ECO:0000269|PubMed:29212708"
FT   COMPBIAS        44..58
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        334..368
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        386..408
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        493..517
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        675..700
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        812..859
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        860..876
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        877..907
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1052..1066
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1409..1424
FT                   /note="Acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1436..1454
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         281
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         540
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         572
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         587
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         635
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0007744|PubMed:20068231"
FT   MOD_RES         641
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:Q69Z38"
FT   MOD_RES         648
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         665
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000269|PubMed:23105102"
FT   MOD_RES         826
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q69Z38"
FT   MOD_RES         854
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         898
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1151
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         1188
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000269|PubMed:23846654"
FT   MOD_RES         1374
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   VARIANT         213
FT                   /note="G -> R (in dbSNP:rs35459975)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041817"
FT   VARIANT         240
FT                   /note="V -> I (in dbSNP:rs56129428)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041818"
FT   VARIANT         440
FT                   /note="S -> P (in dbSNP:rs35335169)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041819"
FT   VARIANT         611
FT                   /note="H -> Q (in a bladder carcinoma NOS sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041820"
FT   VARIANT         792
FT                   /note="S -> I (in dbSNP:rs34885462)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041821"
FT   VARIANT         836
FT                   /note="D -> E (in dbSNP:rs56388121)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041822"
FT   VARIANT         1035
FT                   /note="S -> F (in a metastatic melanoma sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041823"
FT   VARIANT         1071
FT                   /note="R -> K (in dbSNP:rs12909704)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041824"
FT   VARIANT         1077
FT                   /note="T -> P (in dbSNP:rs56133554)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041825"
FT   VARIANT         1145
FT                   /note="P -> L (in a metastatic melanoma sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041826"
FT   VARIANT         1408
FT                   /note="P -> Q (in dbSNP:rs56079860)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041827"
FT   VARIANT         1542
FT                   /note="S -> T (in dbSNP:rs1867780)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041828"
FT   VARIANT         1699
FT                   /note="R -> G (in dbSNP:rs34004337)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041829"
FT   MUTAGEN         665
FT                   /note="Y->E: No effect on localization with actin.
FT                   Decreases localization in focal adhesion. Fails to regulate
FT                   focal adhesion dynamics. Decreases cell migration."
FT                   /evidence="ECO:0000269|PubMed:23105102"
FT   MUTAGEN         665
FT                   /note="Y->F: No effect on focal adhesion subcellular
FT                   localization. Does not affect colocalization with F-actin."
FT                   /evidence="ECO:0000269|PubMed:23105102"
FT   MUTAGEN         1188
FT                   /note="Y->F: Fails to bind SHC1."
FT                   /evidence="ECO:0000269|PubMed:23846654"
FT   MUTAGEN         1609
FT                   /note="F->A: No effect on interaction with PRAG1."
FT                   /evidence="ECO:0000269|PubMed:29079850"
FT   MUTAGEN         1707
FT                   /note="A->D: Disrupts homodimerization."
FT                   /evidence="ECO:0000269|PubMed:29212708"
FT   CONFLICT        779
FT                   /note="S -> F (in Ref. 2; BAC87076)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1046..1049
FT                   /note="SHMT -> RYVK (in Ref. 2; AK091802)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1112..1120
FT                   /note="QSRAAMIPP -> KCKCPISSI (in Ref. 3; BAB84983)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1375..1378
FT                   /note="LAVR -> SQEF (in Ref. 2; BAC87076)"
FT                   /evidence="ECO:0000305"
FT   HELIX           1286..1309
FT                   /evidence="ECO:0007829|PDB:6BHC"
FT   HELIX           1323..1326
FT                   /evidence="ECO:0007829|PDB:6BHC"
FT   STRAND          1327..1330
FT                   /evidence="ECO:0007829|PDB:6BHC"
FT   STRAND          1335..1337
FT                   /evidence="ECO:0007829|PDB:6BHC"
FT   STRAND          1339..1348
FT                   /evidence="ECO:0007829|PDB:6BHC"
FT   STRAND          1351..1361
FT                   /evidence="ECO:0007829|PDB:6BHC"
FT   HELIX           1374..1379
FT                   /evidence="ECO:0007829|PDB:6BHC"
FT   STRAND          1393..1398
FT                   /evidence="ECO:0007829|PDB:6BHC"
FT   HELIX           1400..1402
FT                   /evidence="ECO:0007829|PDB:6BHC"
FT   STRAND          1456..1465
FT                   /evidence="ECO:0007829|PDB:6BHC"
FT   HELIX           1471..1476
FT                   /evidence="ECO:0007829|PDB:6BHC"
FT   HELIX           1479..1484
FT                   /evidence="ECO:0007829|PDB:6BHC"
FT   HELIX           1486..1507
FT                   /evidence="ECO:0007829|PDB:6BHC"
FT   HELIX           1508..1510
FT                   /evidence="ECO:0007829|PDB:6BHC"
FT   HELIX           1519..1521
FT                   /evidence="ECO:0007829|PDB:6BHC"
FT   STRAND          1522..1525
FT                   /evidence="ECO:0007829|PDB:6BHC"
FT   STRAND          1550..1553
FT                   /evidence="ECO:0007829|PDB:6BHC"
FT   HELIX           1574..1576
FT                   /evidence="ECO:0007829|PDB:6BHC"
FT   HELIX           1579..1583
FT                   /evidence="ECO:0007829|PDB:6BHC"
FT   HELIX           1590..1602
FT                   /evidence="ECO:0007829|PDB:6BHC"
FT   HELIX           1608..1611
FT                   /evidence="ECO:0007829|PDB:6BHC"
FT   TURN            1616..1619
FT                   /evidence="ECO:0007829|PDB:6BHC"
FT   TURN            1622..1624
FT                   /evidence="ECO:0007829|PDB:6BHC"
FT   HELIX           1635..1645
FT                   /evidence="ECO:0007829|PDB:6BHC"
FT   TURN            1650..1652
FT                   /evidence="ECO:0007829|PDB:6BHC"
FT   HELIX           1656..1667
FT                   /evidence="ECO:0007829|PDB:6BHC"
FT   HELIX           1672..1680
FT                   /evidence="ECO:0007829|PDB:6BHC"
FT   HELIX           1684..1709
FT                   /evidence="ECO:0007829|PDB:6BHC"
FT   HELIX           1719..1730
FT                   /evidence="ECO:0007829|PDB:6BHC"
FT   HELIX           1733..1743
FT                   /evidence="ECO:0007829|PDB:6BHC"
SQ   SEQUENCE   1746 AA;  193106 MW;  7C9A9F60BBCF6C61 CRC64;
     MSACNTFTEH VWKPGECKNC FKPKSLHQLP PDPEKAPITH GNVKTNANHS NNHRIRNTGN
     FRPPVAKKPT IAVKPTMIVA DGQSICGELS IQEHCENKPV IIGWNRNRAA LSQKPLNNNN
     EDDEGISHVP KPYGNNDSAK KMSDNNNGLT EVLKEIAGLD TAPQIRGNET NSRETFLGRI
     NDCYKRSLER KLPPSCMIGG IKETQGKHVI LSGSTEVISN EGGRFCYPEF SSGEESEEDV
     LFSNMEEEHE SWDESDEELL AMEIRMRGQP RFANFRANTL SPVRFFVDKK WNTIPLRNKS
     LQRICAVDYD DSYDEILNGY EENSVVSYGQ GSIQSMVSSD STSPDSSLTE ESRSETASSL
     SQKICNGGLS PGNPGDSKDM KEIEPNYESP SSNNQDKDSS QASKSSIKVP ETHKAVLALR
     LEEKDGKIAV QTEKEESKAS TDVAGQAVTI NLVPTEEQAK PYRVVNLEQP LCKPYTVVDV
     SAAMASEHLE GPVNSPKTKS SSSTPNSPVT SSSLTPGQIS AHFQKSSAIR YQEVWTSSTS
     PRQKIPKVEL ITSGTGPNVP PRKNCHKSAP TSPTATNISS KTIPVKSPNL SEIKFNSYNN
     AGMPPFPIII HDEPTYARSS KNAIKVPIVI NPNAYDNLAI YKSFLGTSGE LSVKEKTTSV
     ISHTYEEIET ESKVPDNTTS KTTDCLQTKG FSNSTEHKRG SVAQKVQEFN NCLNRGQSSP
     QRSYSSSHSS PAKIQRATQE PVAKIEGTQE SQMVGSSSTR EKASTVLSQI VASIQPPQSP
     PETPQSGPKA CSVEELYAIP PDADVAKSTP KSTPVRPKSL FTSQPSGEAE APQTTDSPTT
     KVQKDPSIKP VTPSPSKLVT SPQSEPPAPF PPPRSTSSPY HAGNLLQRHF TNWTKPTSPT
     RSTEAESVLH SEGSRRAADA KPKRWISFKS FFRRRKTDEE DDKEKEREKG KLVGLDGTVI
     HMLPPPPVQR HHWFTEAKGE SSEKPAIVFM YRCDPAQGQL SVDQSKARTD QAAVMEKGRA
     ENALLQDSEK KRSHSSPSQI PKKILSHMTH EVTEDFSPRD PRTVVGKQDG RGCTSVTTAL
     SLPELEREDG KEDISDPMDP NPCSATYSNL GQSRAAMIPP KQPRQPKGAV DDAIAFGGKT
     DQEAPNASQP TPPPLPKKMI IRANTEPISK DLQKSMESSL CVMANPTYDI DPNWDASSAG
     SSISYELKGL DIESYDSLER PLRKERPVPS AANSISSLTT LSIKDRFSNS MESLSSRRGP
     SCRQGRGIQK PQRQALYRGL ENREEVVGKI RSLHTDALKK LAVKCEDLFM AGQKDQLRFG
     VDSWSDFRLT SDKPCCEAGD AVYYTASYAK DPLNNYAVKI CKSKAKESQQ YYHSLAVRQS
     LAVHFNIQQD CGHFLAEVPN RLLPWEDPDD PEKDEDDMEE TEEDAKGETD GKNPKPCSEA
     ASSQKENQGV MSKKQRSHVV VITREVPCLT VADFVRDSLA QHGKSPDLYE RQVCLLLLQL
     CSGLEHLKPY HVTHCDLRLE NLLLVHYQPG GTAQGFGPAE PSPTSSYPTR LIVSNFSQAK
     QKSHLVDPEI LRDQSRLAPE IITATQYKKC DEFQTGILIY EMLHLPNPFD ENPELKEREY
     TRADLPRIPF RSPYSRGLQQ LASCLLNPNP SERILISDAK GILQCLLWGP REDLFQTFTA
     CPSLVQRNTL LQNWLDIKRT LLMIKFAEKS LDREGGISLE DWLCAQYLAF ATTDSLSCIV
     KILQHR
//
